Prednisone (or equivalent)

DRUG3 trials

Conditions

B-cell Non-Hodgkin LymphomaChronic Lymphocytic LeukaemiaDiffuse Large B Cell LymphomaLarge B-cell LymphomaLymphomaMantle-cell LymphomaNon Hodgkin LymphomaSmall Lymphocytic Lymphoma

Phase 1

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

RecruitingNCT06564038

AstraZenecaB-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Large B-cell Lymphoma +2

Start: 2025-01-30End: 2028-02-28Target: 276Updated: 2026-02-05

Phase 2

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

NCT05200312

The First Affiliated Hospital with Nanjing Medical UniversityDiffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma

Start: 2022-02-01End: 2025-02-01Target: 36Updated: 2022-03-11

Phase 3

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

CompletedNCT01855750

Janssen Research & Development, LLCLymphoma

Start: 2013-09-03End: 2019-04-05Updated: 2025-02-04

2025-10-24

SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.

Journal of Clinical Oncology2025-05-28

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Blood Advances2025-03-145 citations

Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.

2024-11-124 citations

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial

Blood Advances2023-01-2531 citations

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Blood2022-11-154 citations

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

eJHaem2022-08-306 citations

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)

HemaSphere2022-06-011 citations

Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation

Blood2021-11-052 citations

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.

2021-11-04221 citations

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Blood2021-08-2435 citations

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Blood2020-11-046 citations

A Phase I/II First-Line Study of R-Chop Plus B-Cell Receptor/NF-κB-Double-Targeting to Molecularly Assess Therapy Response

International Journal of Hematologic Oncology2019-12-018 citations

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Blood2019-11-1311 citations

CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B‐CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL

Hematological Oncology2019-06-01

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

2019-04-01189 citations

A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).

Journal of Clinical Oncology2014-05-2015 citations

Prednisone (or equivalent)

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers